Stomach cancer just got a major blow—Cogent’s new drug combo (bezuclastinib + sunitinib) slashed the risk of disease progression or death by 50% compared to the old standard. The FDA even gave it Breakthrough Therapy status! Patients in the trial lived almost twice as long without their cancer getting worse. Next up: more trials and a big medical reveal in 2026. Huge hope for GIST patients! #Health #BodyHealth #CancerResearch